Edwards Lifesciences Corp (EW) — Analysis Summary
Edwards Lifesciences Corp (EW) has a market cap of $51.85B with year-over-year revenue growth of +11.5%. Net margin stands at 17.7%. The stock trades at a P/E ratio of 51.6.
Key Takeaways
- Revenue changed +11.5% year-over-year
- Net margin of 17.7%
- P/E ratio of 51.6
Compared to other companies in the ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES sector, EW posted revenue growth of +11.5% and trades at a P/E of 51.6.
Edwards Lifesciences Corp (EW)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Sector
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Employees
16,000
Headquarters
IRVINE, CA
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.